Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2015-04-10 | Mr. Erck has over 30 years of executive leadership experience in the pharmaceutical industry. He has served as President, CEO and Director of Novavax, Inc., a publicly traded biopharmaceutical company. |
| 2016-04-11 | Mr. Erck has over 30 years of executive leadership experience in the pharmaceutical industry... Mr. Erck’s executive experience in the biotech industry and his management positions with major pharmaceutical companies, including his experience with late-stage product candidate development, provide an excellent background for service on the Board. |
| 2017-04-12 | Mr. Erck has over 30 years of executive leadership experience in the pharmaceutical industry... He received his undergraduate degree from the University of Illinois and his MBA from the University of Chicago Graduate School of Business. |
| 2018-05-10 | Mr. Erck has over 30 years of executive leadership experience in the pharmaceutical industry. |
| 2018-09-28 | 2017 DIRECTOR COMPENSATION table and related narrative list Stanley C. Erck as a non-employee director with no mention of technical skills. |
| Filing Date | Source Excerpt |
|---|---|
| 2011-04-29 | Mr. Erck served as CEO of biotechnology companies and has leadership skills. |
| 2012-04-30 | President and Chief Executive Officer of Novavax since April 2011. Former Executive Chairman and Director of Novavax from February 2010 until April 2011, and a Director since June 2009. From 2000 to 2008, Mr. Erck served as President, Chief Executive Officer and Director of Iomai Corporation, a vaccine development company. |
| 2013-04-30 | President and Chief Executive Officer of Novavax since April 2011. Former Executive Chairman and Director of Novavax from February 2010 until April 2011, and a Director since June 2009. From 2000 to 2008, Mr. Erck served as President, Chief Executive Officer and Director of Iomai Corporation, a vaccine development company, which was acquired in 2008 by Intercell. He previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now known as Genzyme, and Baxter International. |
| 2014-04-30 | President and Chief Executive Officer of Novavax, Inc., since April 2011. Former Executive Chairman and Director of Novavax, Inc. from February 2010 until April 2011, and a Director since June 2009. From 2000 to 2008, Mr. Erck served as President, Chief Executive Officer and Director of Iomai Corporation, a vaccine development company, which was acquired in 2008 by Intercell. Prior to that, Mr. Erck previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now known as Genzyme Corporation, and Baxter International. Mr. Erck serves as a member of the boards of BioCryst Pharmaceuticals, MaxCyte, Inc., and the MdBio Foundation. We believe that Mr. Erck is well-suited to serve on our Board due to his entrepreneurial and leadership experience in the biotechnology industry, having grown and provided successful exit strategies, including two IPOs and an acquisition, for several companies, and his extensive experience of serving on other companies’ boards. |
| 2015-04-30 | Mr. Erck received a B.S. in Economics from the University of Illinois and a M.B.A. from the University of Chicago. We believe that Mr. Erck is well-suited to serve on our Board due to his leadership experience in the biotechnology industry. |
| 2016-04-20 | Mr. Erck received a B.S. in economics from the University of Illinois and a M.B.A from the University of Chicago. |
| 2017-04-28 | Mr. Erck received a B.S. in economics from the University of Illinois and a M.B.A from the University of Chicago. |
| 2018-04-30 | Mr. Erck received a B.S. in economics from the University of Illinois and a M.B.A from the University of Chicago. We believe that Mr. Erck is well-suited to serve on our Board due to his leadership experience in the biotechnology industry. |
| 2019-05-16 | Mr. Erck received a B.S. in economics from the University of Illinois and a M.B.A from the University of Chicago. We believe that Mr. Erck is well-suited to serve on our Board due to his leadership experience in the biotechnology industry, having held chief executive officer positions for several companies, and his extensive experience of serving on other companies’ boards. |
| 2020-05-13 | Mr. Erck received a B.S. in economics from the University of Illinois and a M.B.A from the University of Chicago. We believe that Mr. Erck is well-suited to serve on our Board due to his leadership experience in the biotechnology industry, having held chief executive officer positions for several companies, and his extensive experience of serving on other companies’ boards. |
| 2021-05-03 | Mr. Erck is well-suited to serve on our Board due to his leadership experience in the biotechnology industry, having held chief executive officer positions for several companies, and his extensive experience of serving on other public company boards. |
| 2022-05-02 | Mr. Erck is well-suited to serve on our Board due to his leadership experience in the biotechnology industry, having held chief executive officer positions for several companies, and his extensive experience of serving on other public company boards. |
Data sourced from SEC filings. Last updated: 2025-10-11